Pazopanib therapy for children, adolescents, and young adults with relapsed and refractory sarcomas
Japanese Journal of Clinical Oncology · 2025
DOI: 10.1093/jjco/hyaf191 ↗Kurz gefasst
Fachartikel in der Zeitschrift Japanese Journal of Clinical Oncology, 2025. Verfasst von Kosuke Tamefusa und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan. Hauptthemen laut MEDLINE: Sulfonamides, Pyrimidines, Sarcoma, Neoplasm Recurrence, Local. Die Arbeit nennt 40 Literaturangaben. Gefördert von: JSPS.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Pazopanib is used to treat relapsed and refractory sarcomas. Pazopanib’s role in pediatric, adolescent, and young adult populations remains unestablished.
Methods
To assess pazopanib’s utility, we analyzed retrospectively collected data from pediatric (0–14 years) and adolescent and young adult (15–39 years) patients diagnosed with relapsed or refractory sarcomas who received pazopanib.
Results
We assessed data from 21 patients (10 pediatric, 11 adolescent, and young adult). Their diagnoses included osteosarcoma (n = 11), rhabdomyosarcoma (n = 4), alveolar soft part sarcoma (n = 5), and leiomyosarcoma (n = 1). Thirteen (62%) patients presented with metastatic disease at the initial diagnosis. Patients had received a median of three prior chemotherapy regimens (range: 0–6). The median duration of pazopanib treatment was 3.5 months (range: 1–12) for pediatric patients and 4 months (range: 1–83) for adolescents and young adults. Nine patients (five adolescents and young adults) discontinued pazopanib owing to disease progression, and two discontinued owing to adverse events (pneumothorax). We observed seven cases of stable disease (four adolescents and young adults) and 12 of progressive disease (six adolescents and young adults) after ~3 months. The median survival following pazopanib initiation was 7.8, 4.8, and 12.4 months for overall, pediatric, and adolescent and young adult patients, respectively.
Conclusions
In a small cohort of children and adolescent and young adult patients with heavily pretreated relapsed or refractory sarcoma, pazopanib may be a feasible option. Further research on optimal therapeutic timing and the target population for pazopanib’s indication is required.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan.
- Department of Orthopedic Surgery, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan.
- Center for Clinical Oncology, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan.
- Department of Pharmacy, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan.
ORCID-Profile: Kosuke Tamefusa
Förderung
- JSPS
Zitieren
APA
Tamefusa, K., Ishida, H., Fujiwara, T., Makimoto, G., Ochi, M., Shiwaku, T., Fujiwara, K., Tatebe, Y., Washio, K., Tabata, M., Ozaki, T., & Tsukahara, H. (2025). Pazopanib therapy for children, adolescents, and young adults with relapsed and refractory sarcomas. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyaf191
Vancouver
Tamefusa K, Ishida H, Fujiwara T, Makimoto G, Ochi M, Shiwaku T, et al. Pazopanib therapy for children, adolescents, and young adults with relapsed and refractory sarcomas. Japanese Journal of Clinical Oncology. 2025. doi:10.1093/jjco/hyaf191
BibTeX
@article{Tamefusa2025,
author = {Tamefusa, Kosuke and Ishida, Hisashi and Fujiwara, Tomohiro and Makimoto, Go and Ochi, Motoharu and Shiwaku, Takahiro and Fujiwara, Kaori and Tatebe, Yasuhisa and Washio, Kana and Tabata, Masahiro and Ozaki, Toshifumi and Tsukahara, Hirokazu},
title = {Pazopanib therapy for children, adolescents, and young adults with relapsed and refractory sarcomas},
journal = {Japanese Journal of Clinical Oncology},
year = {2025},
doi = {10.1093/jjco/hyaf191}
}
EUVIMED